ORIGINAL ARTICLE |
|
Year : 2013 | Volume
: 17
| Issue : 8 | Page : 449-452 |
|
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Southwest Saudi Arabia cohort of the A 1 chieve study
Waffaa Shawkat1, Magdy Abdou2, Nadia Ghannam3, Ashraf Shaaban Mahfouz4
1 Department of Diabetes center, Saudi German hospital, Abha, Southwest Saudi Arabia 2 Department of Internal Medicine, Saudi Airlines Medical Center, Jeddah, Western Saudi Arabia 3 Department of Diabetes center of excellence, International Medical Center, Jeddah, Western Saudi Arabia 4 Ghassan Naguib Pharoun Hospital, Jeddah, Western Saudi Arabia
Correspondence Address:
Waffaa Shawkat Saudi German hospital, Abha Southwest Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.122070
|
|
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. Materials and Methods: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from southwest Saudi Arabia. Results: A total of 2561 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (n = 987), insulin detemir (n = 1121), insulin aspart (n = 21), basal insulin plus insulin aspart (n = 280) and missing or other insulin combinations (n = 152). At baseline glycaemic control was poor for both insulin naïve (mean HbA 1 c: 9.9%) and insulin user (mean HbA 1 c: 9.5%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA 1 c (insulin naïve: −2.5%, insulin users: −2.2%). Major hypoglycaemic events did not occur in any of the study patients. SADRs were reported in 0.1% of insulin naïve and 0.1% of insulin user groups. Conclusion: Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|